Survodutide

Survodutide (BI 456906) is an investigational dual glucagon/GLP-1 receptor agonist administered once weekly for the treatment of obesity and metabolic dysfunction-associated steatohepatitis by simultaneously increasing energy expenditure and reducing food intake.

Brief glance

The primary outcome is Weight Loss, but it's also used for Metabolic, Longevity. This compound is considered a Peptide. It is not currently indicated as compoundable in 503A pharmacies. It is not listed under a DEA schedule.

Overview

Survodutide (BI 456906) is an investigational dual glucagon/GLP-1 receptor agonist administered as a once-weekly subcutaneous injection, designed to promote weight loss through both increased energy expenditure and reduced food intake. The medication is currently in clinical development for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH), with early trial data demonstrating approximately 7-9% body weight reduction at doses of 2.4-4.8 mg weekly. Its dual mechanism differentiates it from standard GLP-1 therapies by combining appetite suppression with hepatic fat metabolism and energy expenditure via glucagon receptor activation.

Survodutide is an investigational pharmaceutical active ingredient classified as a dual agonist of the glucagon and glucagon-like peptide-1 (GLP-1) receptors. It is designed for once-weekly subcutaneous administration, leveraging GLP-1 receptor activation to reduce appetite, slow gastric emptying, improve glycemic control, and suppress glucagon release, while glucagon receptor stimulation increases energy expenditure, promotes lipolysis, and enhances liver fat metabolism. This combined mechanism supports its development primarily for obesity, where clinical trials have shown average body weight reductions of 7-9% over 4-11 months, as well as for metabolic dysfunction-associated steatohepatitis (MASH), with demonstrated improvements in liver histology and fibrosis after 48 weeks. Survodutide has received Fast Track and Breakthrough Therapy Designations from the FDA, along with PRIME status from the EMA, for MASH with fibrosis, reflecting its potential in addressing obesity-related comorbidities. Developed through a collaboration between Boehringer Ingelheim and Zealand Pharma, it remains in phase 3 trials for these indications.

Benefits

Survodutide, a glucagon/GLP-1 receptor dual agonist, demonstrated clinically significant weight loss of up to 18.7-19% over 46 weeks in phase 2 trials for adults with overweight or obesity without diabetes, alongside reductions in waist circumference, blood pressure, and triglycerides.¹,²,³,⁴ In patients with type 2 diabetes and obesity, it reduced HbA1c by up to 1.71-1.88% over 16 weeks, with concurrent weight loss and improved lipid profiles.¹,³ Phase 2 data also showed improvements in metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis after 48 weeks, supporting its investigational role in obesity-related comorbidities.² These effects stem from GLP-1 receptor-mediated appetite suppression and insulin secretion alongside glucagon receptor-driven energy expenditure and fat metabolism.¹,²

Side effects

The most common side effects of survodutide are gastrointestinal disorders, including nausea, vomiting, diarrhea, constipation, and indigestion, reported in 55-75% of patients across phase 2 trials and often most pronounced during dose escalation, leading to discontinuation rates of 16-25%.⁵,⁶,⁷ These effects are typically mild to moderate, temporary, and improve with time or gradual dose increases, though they can cause dehydration, fatigue, reduced appetite, or increased heart rate in some cases.⁵,⁶,⁸ Serious adverse events are rare and similar to placebo rates (around 7-8%), but include risks of pancreatitis, gallbladder issues (e.g., gallstones from rapid weight loss), severe dehydration potentially leading to renal failure, low blood sugar (especially with concomitant diabetes medications), and a theoretical concern for thyroid tumors based on animal data.⁵,⁶ Key safety considerations involve monitoring for severe abdominal pain, persistent vomiting, dehydration symptoms, or yellowing of skin/eyes, with contraindications for those with a history of thyroid cancer or pancreatitis; long-term safety data remain limited as phase 3 trials progress.⁵,⁶,⁹

Mechanisms of action

Survodutide acts as a dual agonist primarily targeting the glucagon-like peptide-1 receptor (GLP-1R) with greater potency (approximately 8:1 ratio compared to glucagon receptor [GCGR] activation) and the glucagon receptor (GCGR).⁷,¹⁰ GLP-1R activation stimulates insulin secretion in a glucose-dependent manner, inhibits glucagon release, delays gastric emptying, and reduces appetite via central hypothalamic and hindbrain pathways, thereby controlling postprandial hyperglycemia and food intake.⁷,¹¹ GCGR activation increases energy expenditure, promotes hepatic lipolysis and fat oxidation, and contributes to weight reduction without significantly worsening glycemic control due to the biased agonism favoring GLP-1R.⁷,¹⁰ This balanced dual mechanism enhances overall metabolic regulation, including reduced hepatic fat content and improved lipid metabolism.¹⁰,¹² The molecule's acylated structure enables albumin binding for an extended half-life, supporting once-weekly subcutaneous dosing.⁷